Published online before print October 19, 2007, doi: 10.1161/ATVBAHA.107.155317
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2008 American Heart Association, Inc.
Brief Review |
Cell-Based Therapy of Myocardial Infarction
From Molecular Cardiology, Department of Internal Medicine III, University of Frankfurt, Germany.
Correspondence to Dr Stefanie Dimmeler, Molecular Cardiology, Department of Internal Medicine III, University of Frankfurt, Theodor Stern-Kai 7, 60590 Frankfurt, Germany. E-mail Dimmeler{at}em.uni-frankfurt.de
Series Editor: Stefanie Dimmeler
Novel Mediators and Mechanisms in Angiogenesis and Vasculogenesis
ATVB In Focus
Previous Brief Reviews in this Series:
•Dimmeler S. Novel mediators and mechanisms in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol. 2005;25:2245.
•Ferguson JE, Kelley RW, Patterson C. Mechanisms of endothelial differentiation in embryonic vasculogenesis. Arterioscler Thromb Vasc Biol. 2005;25:2246–2254.
•Werner N, Nickenig G. Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy? Arterioscler Thromb Vasc Biol. 2006;26:257–266.
•van Hinsbergh VWM, Engelse MA, Quax PHA. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol. 2006;26:716–728.
•Sata M. Role of circulating vascular progenitors in angiogenesis, vascular healing, and pulmonary hypertension: lessons from animal models. Arterioscler Thromb Vasc Biol. 2006;26:1008–1014.
Cell-based therapy is a promising option for treatment of ischemic diseases. Several cell types have experimentally been shown to increase the functional recovery of the heart after ischemia by physically forming new blood vessels, differentiating to cardiac myocytes and—additionally or alternatively—by providing proangiogenic and antiapoptotic factors promoting tissue repair in a paracrine manner. Clinical studies preferentially used adult bone marrow–derived cells for the treatment of patients with acute myocardial infarction. Most of the studies suggested that cell therapy reduced the infarct size and improved cardiac contractile function. However, cell therapy is in its early stages, and various questions remain. For example, the identification of those patients who benefit most from cell therapy, the optimal cell type and number for patient with acute and chronic diseases, the best time and way of cell delivery, and the mechanisms of action by which cells exhibit beneficial effects, need to be further evaluated. Although no major safety concerns were raised during the initial clinical trials, several potential side effects need to be carefully monitored. The present review article summarizes the results of the clinical studies and discusses the open issues.
Cell based therapy is a promising option for treatment of ischemic diseases. Several cell types have been shown to increase the functional recovery of the heart after ischemia. The present review article summarizes the results of the experimental and clinical studies and discusses open questions in cell-based therapies.
Key Words: cell therapy • neovascularization • stem cells • acute myocardial infarction
This article has been cited by other articles:
 |
|
 |
|
  P. Tossios, B. Krausgrill, M. Schmidt, T. Fischer, M. Halbach, J. W.U. Fries, S. Fahnenstich, P. Frommolt, I. Heppelmann, A. Schmidt, et al. Role of balloon occlusion for mononuclear bone marrow cell deposition after intracoronary injection in pigs with reperfused myocardial infarction Eur. Heart J., June 10, 2008; (2008) ehn218v1. [Abstract] [Full Text] [PDF]
|
|